Estimating the Size of the Effects of Co-Medications on Plasma Clozapine Concentrations using a Model that Controls for Clozapine Doses and Confounding Variables

 

 Buy Article Permissions and Reprints

Abstract

Aim: The purpose of this study was to estimate the effect sizes of drug interactions on plasma clozapine concentrations, adjusting for potentially confounding factors such as smoking.

Methods: The estimation was performed by using a mixed model, and a combination of unpublished (N=83) and published (N=172) data that included patients taking phenobarbital, valproic acid, fluvoxamine, fluoxetine, paroxetine, sertraline, citalopram and reboxetine, and patients not taking co-medications.

Results: The 255 patients provided a total of 415 steady-state trough plasma clozapine concentrations. Each patient provided 1 to 15 measures of plasma clozapine concentrations. Total plasma clozapine concentration, defined as the sum of plasma clozapine and norclozapine concentrations, was also investigated. A random intercept linear model of the natural log of plasma clozapine concentration with the natural log of dose and other variables as independent variables was built. The model confirmed that phenobarbital induces clozapine metabolism (effect size, E=-28%), and that fluoxetine (E=+42%), fluvoxamine (E=+263%) and paroxetine (E=+30%) inhibit it. Valproic acid appeared to inhibit clozapine metabolism in non-smokers (effect size, E=+16%), whereas it appeared to induce clozapine metabolism in smokers (E=-22%). The effect sizes of smoking on plasma clozapine concentration were -20% in patients not taking valproic acid, and -46% in patients taking valproic acid. Thus, smoking induces clozapine metabolism, and this induction may be stronger when the patient is taking valproic acid. The effect sizes allowed the computation of clozapine dose-correction factors for phenobarbital, 1.4 [95% confidence interval, CI, (1.1, 1.7)]; paroxetine, 0.77 (0.67, 0.89); fluoxetine, 0.70 (0.64, 0.78); fluvoxamine, 0.28 (0.22, 0.35); and valproic acid [0.86 (0.75, 1.0) in non-smokers, and 1.3 (0.96, 1.73) in smokers]. Sertraline, reboxetine and citalopram had no obvious effects.

Discussion: The results for total plasma clozapine concentrations are similar to those for plasma clozapine concentrations. The main limitations of this study were that the computed effect sizes reflect only the doses and treatment-durations of the co-medications studied, and that the substantial “noise” of the clinical environment may make it difficult to detect the effects of some variables, particularly those with small effect sizes. Gender was not significant probably due to its relatively small effect size in the studied population, and age was not significant probably due to the limited age variability.

Conclusion: This article contributes to the clozapine literature by describing a possible interaction between taking valproic acid and smoking, which modifies plasma clozapine concentrations, by estimating the effect sizes of other compounds on plasma clozapine concentrations after correcting for confounders, and by providing dose-correction factors for clinicians.

References

• 1 Avenoso A, Facciola G, Campo GM, Fazio A, Spina E. Determination of clozapine, desmethylclozapine and clozapine N-oxide in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection.  J Chromatogr B Biomed Sci Appl. 1998;  714 299-308
  PubMedGoogle Scholar
• 2 Avenoso A, Facciolà G, Scordo MG, Gitto C, Drago Ferrante G, Madia AG. et al . No effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with schizophrenia.  Clin Drug Invest. 1998;  16 393-398
  PubMedGoogle Scholar
• 3 Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M. et al . The AGNP-TDM expert group consensus guidelines: therapeu-tic drug monitoring in psychiatry.  Pharmacopsychiatry. 2004;  37 243-256
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Brown H, Prescott R. Applied mixed models in medicine. Hoboken, NJ: John Wiley & Sons 2001
• 5 Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients.  J Clin Psychopharmacol. 1994;  14 119-125
  PubMedGoogle Scholar
• 6 Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR. et al . Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate.  Am J Psychiatry. 1994;  151 123-125
  CrossrefPubMedGoogle Scholar
• 7 Conca A, Beraus W, Konig P, Waschgler R. A case of pharmacokinetic interference in comedication of clozapine and valproic acid.  Pharmacopsychiatry. 2000;  33 234-235
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Davidian M, Giltinan DM. Nonlinear models for repeated measurement data. Boca Raton, FL: Chapman & Hall/CRC 1995
• 9 de Leon J. Glucuronidation enzymes, genes and psychiatry.  Int J Neuropsychopharmacology. 2003;  6 57-72
  CrossrefPubMedGoogle Scholar
• 10 de Leon J. Psychopharmacology. Atypical antipsychotic dosing: The effect of co-medication with anticonvulsants.  Psychiatr Serv. 2004;  55 125-128
  CrossrefPubMedGoogle Scholar
• 11 de Leon J. Psychopharmacology. Atypical antipsychotic dosing: the effect of smoking and caffeine.  Psychiatr Serv. 2004;  55 491-493
  CrossrefPubMedGoogle Scholar
• 12 de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics.  Psychosomatics. 2005;  46 262-273
  CrossrefPubMedGoogle Scholar
• 13 de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: A case report.  Prog Neuro-Psychopharmacol Biol Psychiatry. 2003;  27 1059-1063
  CrossrefPubMedGoogle Scholar
• 14 de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors.  Schizophr Res. 2005;  76 135-157
  CrossrefPubMedGoogle Scholar
• 15 de Leon J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM. Does clozapine decrease smoking?.  Prog Neuro-Psychopharmacol Biol Psychiatry. 2005;  29 757-762
  CrossrefPubMedGoogle Scholar
• 16 de Leon J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM. Weight gain during a double-blind multi-dosage clozapine study.  J Clin Psychopharmacol. 2007;  127 22-27
  PubMedGoogle Scholar
• 17 de Leon J, Diaz F, Rogers T, Browne D, Dinsmore L, Ghosheh O. et al . A pilot study of plasma caffeine concentrations in a US sample of smokers and non-smokers volunteers.  Prog Neuro-Psychopharmacol Biol Psychiatry. 2003;  27 165-171
  CrossrefPubMedGoogle Scholar
• 18 de Leon J, Odom-White A, Josiassen RC, Diaz FJ, Cooper TB, Simpson GM. Serum muscarinic activity during clozapine treatment.  J Clin Psychopharmacology. 2003;  23 336-341
  PubMedGoogle Scholar
• 19 de Leon J, Susce MT, Johnson M, Hardin M, Pointer L, Ruaño G. et al . A clinical study of the association of antipsychotics with hyperlipidemia.  Schizophr Res. 2007;  92 95-102
  CrossrefPubMedGoogle Scholar
• 20 de Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.  Pharmacopsychiatry. 2007;  40 93-102
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Dettling M, Sachse C, Brockmoller J, Schley J, Mueller-Oerlinghausen B, Pickersgill I. et al . Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients.  Psychopharmacology. 2000;  152 80-86
  CrossrefPubMedGoogle Scholar
• 22 Diaz FJ, Rivera TE, Josiassen RC, de Leon J. Individualizing drug dosage by using a random intercept linear model.  Statist Med. 2007;  26 2052-2073
  CrossrefPubMedGoogle Scholar
• 23 Facciolà GA, Avenoso E, Spina E, Perucca E. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia.  Ther Drug Monit. 1998;  20 628-630
  CrossrefPubMedGoogle Scholar
• 24 Facciola G, Avenoso A, Scordo MG, Madia AG, Ventimiglia A, Perucca E. et al . Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders.  Ther Drug Monit.. 1999;  21 341-345
  CrossrefPubMedGoogle Scholar
• 25 Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition.  Biol Psychiatry. 1994;  36 487-488
  PubMedGoogle Scholar
• 26 Haring C, Meise U, Humpel C, Saria A, Fleishhacker WW, Hinterhuber H. Dose-related plasma levels of clozapine: influence of smoking behavior, sex and age.  Psychopharmacology. 1989;  99 S38-S40
  CrossrefPubMedGoogle Scholar
• 27 Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A. Influence of patient-related variables on clozapine plasma levels.  Am J Psychiatry. 1990;  147 1471-1475
  PubMedGoogle Scholar
• 28 Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking.  J Clin Psychopharmacol. 1993;  13 383-390
  PubMedGoogle Scholar
• 29 Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H. The effect of variable consumption on the interaction with clozapine and olanzapine.  Eur J Clin Pharmacol. 2006;  62 1049-1053
  CrossrefPubMedGoogle Scholar
• 30 Hendset M, Haslemo T, Rudberg I, Refsum H, Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs.  Pharmacopsychiatry. 2006;  39 121-127
  Article in Thieme ConnectPubMedGoogle Scholar
• 31 Hiemke C, Weighmann H, Hartter S, Dahmen N, Wetzel H, Muller H. Elevated serum levels of clozapine after addition of fluvoxamine (letter).  J Clin Psychopharmacol. 1994;  14 279-281
  PubMedGoogle Scholar
• 32 Hiemke C, Dragicevic A, Grunder G, Hatter S, Sachse J, Vernaleken I. et al . Therapeutic drug monitoring of new antipsychotic drugs.  Ther Drug Monit. 2004;  26 156-160
  CrossrefPubMedGoogle Scholar
• 33 Kronig MH, Munne RH, Szymanski S, Safferman AZ, Pollack S, Cooper T. et al . Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.  Am J Psychiatry. 1995;  152 179-182
  PubMedGoogle Scholar
• 34 Kuoppamaki M, Syvalahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT_1C receptor antagonists.  Eur J Pharmacol-Mol Pharmacol Section. 1993;  245 179-182
  PubMedGoogle Scholar
• 35 Lane HY, Chang YC, Lin SK, Tseng YT, Jann MW. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics.  J Clin Psychiatry. 1999;  60 36-40
  CrossrefPubMedGoogle Scholar
• 36 Littell RC, Milliken GA, Stroup WW, Wolfinger RD, Schabenberger O. SAS for Mixed Models. Second Edition. Cary, NC: SAS Institute Inc. 2006
• 37 Longo LP, Salzman C. Valproic acid effects on serum concentrations of clozapine and norclozapine.  Am J Psychiatry. 1995;  152 650
  PubMedGoogle Scholar
• 38 Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.  J Clin Psychiatry. 2004;  65 766-771
  CrossrefPubMedGoogle Scholar
• 39 Ozdemir V, Kalow W, Posner P, Collins EJ, Kennedy JL, Tang BK. et al . CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia.  J Clin Psychopharmacol. 2002;  21 398-407
  PubMedGoogle Scholar
• 40 Palego L, Biondi L, Giannaccini G, Sarno N, Elmi S, Ciapparelli A. et al . Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables.  Prog Neuro-Psychopharmacol Biol Psychiatry. 2002;  26 473-480
  CrossrefPubMedGoogle Scholar
• 41 Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenia patients.  Am J Psychiatry. 1991;  148 231-235
  PubMedGoogle Scholar
• 42 Perry PJ, Bever KA, Arndt S, Combs MD. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram.  Biol Psychiatry. 1998;  44 733-738
  CrossrefPubMedGoogle Scholar
• 43 Pinninti NR, de Leon J. Interaction of sertraline with clozapine (letter).  J Clin Psychopharmacology. 1997;  17 119-120
  CrossrefPubMedGoogle Scholar
• 44 Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.  J Clin Psychopharmacol. 2004;  24 70-78
  CrossrefPubMedGoogle Scholar
• 45 Simpson GM, Josiassen RC, Stanilla JK, de Leon J, Nair C, Abraham G. et al . Double-blind study of clozapine dose response in chronic schizophrenia.  Am J Psychiatry. 1999;  156 1744-1750
  PubMedGoogle Scholar
• 46 Spina E, Avenoso G, Facciolà M, Fabrazzo M, Monteleone P, Maj M. et al . Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.  Int Clin Psychopharmacol. 1998;  13 141-145
  CrossrefPubMedGoogle Scholar
• 47 Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia AG. et al . Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.  Psychopharmacology. 2000;  148 83-89
  CrossrefPubMedGoogle Scholar
• 48 Spina E, Avenoso A, Salemi M, Facciola G, Scordo MG, Ancione M. et al . Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline.  Pharmacopsychiatry. 2000;  33 213-217
  Article in Thieme ConnectPubMedGoogle Scholar
• 49 Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Levita A. No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites.  Ther Drug Monit. 2001;  23 675-678
  PubMedGoogle Scholar
• 50 Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review.  Basic Clin Pharmacol Tox. 2007;  100 4-22
  CrossrefPubMedGoogle Scholar
• 51 Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB. et al . N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity.  Proc Natl Acad Sci USA. 2003;  100 13674-13679
  CrossrefPubMedGoogle Scholar
• 52 Tang YL, Mao P, Li FM, Li W, Chen Q, Jiang F. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia.  Br J Clin Pharmacol. 2007;  64 49-56
  CrossrefPubMedGoogle Scholar
• 53 Ulrich S, Baumann B, Wolf R, Lehmann D, Peters B, Bogerts B. et al . Therapeutic drug monitoring of clozapine and relapse - a retrospective study of routine clinical data.  Int J Clin Pharmacol Ther. 2003;  41 3-13
  CrossrefPubMedGoogle Scholar
• 54 van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement.  Pharmacogenetics. 2003;  13 169-172
  CrossrefPubMedGoogle Scholar
• 55 VenderZwaag C, MacGee M, MacEvoy JP, Freudenreich O, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges.  Am J Psychiatry. 1996;  153 1579-1584
  PubMedGoogle Scholar
• 56 Wong JO, Leung SP, Mak T, Ng RM, Chan KT, Cheung HH. et al . Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients.  Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;  30 251-264
  CrossrefPubMedGoogle Scholar
• 57 Woodward M. Epidemiology: Study Design and Data Analysis. Chapman & Hall/CRC, Boca Raton, FL 1999
• 58 Zink M, Englisch S, Knopf U, Kuwilsky A, Dressing H. Augmentation of clozapine with valproic acid for clozapine-induced obsessive-compulsive symptoms.  Pharmacopsychiatry. 2007;  40 202-203
  Article in Thieme ConnectPubMedGoogle Scholar

Correspondence

J. de LeonMD 

Mental Health Research Center at Eastern State Hospital

627 West Fourth St.

Lexington

KY 40508

USA

Phone: +1/859/246 75 63

Fax: +1/859/246 70 19

Email: jdeleon@uky.edu